Company Overview and News

 
DoT to issue notice to five telcos to recover Rs 2,578 cr

2017-12-31 moneycontrol
The Department of Telecom (DoT) will issue notice to five telecom operators, including Tata Teleservices, Telenor and Reliance Jio, to recover Rs 2,578 crore, in the wake of the CAG red-flagging understatement of revenues by the firms.
Upvote Downvote

 
Tata Tele, Telenor, 3 others understated revenue by Rs 14,000 crore

2017-12-19 moneycontrol
Tata Teleservices, Telenor, Videocon and Reliance Jio are among five telecom firms which have understated revenues by over Rs 14,800 crore, resulting in a shortfall of nearly Rs 2,578 crore to the exchequer, government auditor CAG said today.
Upvote Downvote

 
Five telecom firms understated AGR by Rs 14,800 cr: CAG

2017-12-19 business-standard
Tata Teleservices, Telenor, Videocon Telecom, Quadrant Televentures, and Reliance Jio Infocomm have understated their adjusted gross revenue (AGR) by over Rs 14,800 crore, which has resulted in a shortfall of Rs 1,526.70 crore to the government, according to a report by the Comptroller and Auditor General (CAG) of India.   The report, tabled in Parliament, states the interest on the short payment stood at Rs 1,052.
Upvote Downvote

 
Quadrant Televentures reports standalone net loss of Rs 48.10 crore in the March 2017 quarter

2017-06-23 indiainfoline
For the full year,net loss reported to Rs 152.08 crore in the year ended March 2017 as against net loss of Rs 134.81 crore during the previous year ended March 2016. Sales declined 5.48% to Rs 527.79 crore in the year ended March 2017 as against Rs 558.37 crore during the previous year ended March 2016.
Upvote Downvote

 
Videocon’s six-fold losses spell trouble for the debt-ridden conglomerate

2017-02-13 livemint
Videocon Industries increaseed their year-long loss to Rs1,367.94 crore—a whopping 24 times higher than the previous year
Upvote Downvote

 
India’s Mobile-Phone Price War Seen Spurring Consolidation - Bloomberg

2017-01-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Company News

2017-01-20 thehindubusinessline
Hindustan Construction Co on Friday said it has allotted 4.155 crore shares and 23.2 lakh optionally-convertible debentures to lenders, under a debt restructuring scheme. The company has allotted 1.586 crore shares to Axis Bank, 2.196 crore shares to Punjab National Bank and 37.3 lakh shares to Standard Chartered Bank. It also allotted 9.74 lakh convertible debentures to Axis Bank and 13.5 lakh CDs to PNB.
Upvote Downvote

 
Videocon Telecom to shut Punjab circle ops from February 15

2017-01-20 moneycontrol
Ensure that your correct email id and mobile has been registered with moneycontrol. If not, please update your profile and secure the account now. Updating your email id and mobile number offers following benefits:
Upvote Downvote

 
Quadrant Televentures reports standalone net loss of Rs 14.89 crore in the March 2016 quarter

2016-05-28 indiainfoline
We encourage visitors to register on IIFL. Registering on the site is absolutely Free and offers you the following benefits.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...